Ernexa Therapeutics Inc. (ERNA) Operating cash flow 2016–2025
Ernexa Therapeutics Inc. (ERNA) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$7.0MFY2025 · since FY2016: $23,000 → -$7.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$7.0M | +55.7% |
| FY2024 | -$15.8M | +22.4% |
| FY2023 | -$20.4M | +2.7% |
| FY2022 | -$21.0M | +10.7% |
| FY2021 | -$23.5M | -189.9% |
| FY2020 | -$8.1M | -395.2% |
| FY2019 | $2.7M | +101.0% |
| FY2018 | $1.4M | +148.6% |
| FY2017 | $549,000 | +2287.0% |
| FY2016 | $23,000 | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ERNA financial trends
ERNA RevenueERNA Net incomeERNA Net marginERNA Gross profitERNA Gross marginERNA Operating incomeERNA Operating marginERNA Free cash flowERNA Capital expendituresERNA Return on equityERNA Stock buybacksERNA Dividends paidERNA Total assetsERNA Total liabilitiesERNA Shareholders’ equityERNA overview →